[A22-68] Secukinumab (juvenile psoriatic arthritis) – Benefit assessment according to §35a Social Code Book V
Last updated 17.10.2022
Project no.:A22-68
Commission:
Commission awarded on 12.07.2022 by the Federal Joint Committee (G-BA).Report type:
Dossier assessmentStatus:Commission completed
Department/Division:
Drug AssessmentTopic:
Skin and hair
Indication:
Alone or in combination with methotrexate for the treatment of active juvenile psoriatic arthritis in patients aged 6 years and older whose disease has responded inadequately to, or who cannot tolerate, conventional therapy
Result of dossier assessment:
Added benefit not proven
Note:
After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the G-BA website.